Abstract
Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH).
Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non-AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4+ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection.
Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4+ 688 cells/mm 3 , 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a seroprevalence of 8.5% (95%CI 6.9-10.3%). Forty-five infections (45.0%) were asymptomatic. Variables independently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41-3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26-0.94, p 0.031).
Conclusions: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH.
Keywords: COVID-19; HIV; SARS-CoV-2; Serology; Seroprevalence.
【저자키워드】 COVID-19, SARS-CoV-2, HIV, serology, Seroprevalence, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, coronavirus, therapy, serology, cross-sectional, SARS-COV-2 infection, severity, Cancer, Seroprevalence, Infection, Comorbidities, Diabetes Mellitus, Comorbidity, Sex, Chronic kidney disease, diabetes, severe acute respiratory syndrome Coronavirus, hypertension, Prevalence, Cohort, SARS-CoV-2 antibodies, cross-sectional study, SARS-CoV-2 antibody, Asymptomatic, Viral load, AIDS, cirrhosis, Antiretroviral therapy, tenofovir disoproxil fumarate, Birth, Spain, Kidney disease, Seropositivity, plasma, age, network, predictor, inhibitor, SARS-CoV-2 infections, nucleotide, Analysis, heart disease, criteria, Illness severity, fumarate, reverse transcriptase, medical records, medical record, tenofovir disoproxil, tenofovir, acute respiratory syndrome, Factor, adjusted odds ratio, Logistic regression analysis, emtricitabine, Tenofovir alafenamide, 95%CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, median age, participant, CD4+, nucleoside, route, Multivariable logistic regression analysis, backbone, sample collection, chronic heart disease, cell count, transcriptase, acquisition, antiretroviral drug, variable, Spanish, country, Prevent, males, other variables, TDF/FTC, identify, was used, collected, carried, median, adjusted, illness, NIH, increased the risk, Latin, people with HIV, undetectable, 【제목키워드】 network, Factor, Spanish,